Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.69 +3.4%	$1.74	$1.41 ▼ $5.01	$9.29M	1.19	27,217 shs	9,146 shs
DOVA Dova Pharmaceuticals	$28.04	$28.04	$5.62 ▼ $28.54	$807.55M	2.74	499,313 shs	35,036 shs
KNSA Kiniksa Pharmaceuticals International	$28.84 +2.7%	$27.76	$17.82 ▼ $30.69	$2.10B	0.05	553,519 shs	62,525 shs
RYTM Rhythm Pharmaceuticals	$90.44 +1.2%	$65.37	$40.61 ▼ $94.80	$5.75B	2.26	587,807 shs	61,308 shs
ZIOP ZIOPHARM Oncology		$1.08	$0.77 ▼ $5.95	$187.12M	1.71	2.01 million shs	2.13 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	-4.12%	-9.44%	-13.76%	+6.04%	-58.42%
DOVA Dova Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
KNSA Kiniksa Pharmaceuticals International	-2.47%	+3.23%	-0.74%	+36.82%	+29.99%
RYTM Rhythm Pharmaceuticals	+0.24%	+37.18%	+42.07%	+45.68%	+72.18%
ZIOP ZIOPHARM Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	2.9304 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	1.3
DOVA Dova Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	3.561 of 5 stars	3.5	4.0	0.0	0.0	3.0	3.3	0.6
RYTM Rhythm Pharmaceuticals	3.1614 of 5 stars	2.5	1.0	0.0	4.3	2.6	0.8	0.6
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	819.88% Upside
DOVA Dova Pharmaceuticals	0.00	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.33	36.41% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.00	0.62% Upside
ZIOP ZIOPHARM Oncology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZIOP, APRE, DOVA, RYTM, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$88.00
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	6.21	N/A	N/A	$3.55 per share	0.47
DOVA Dova Pharmaceuticals	$10.35M	78.02	N/A	N/A	$2.71 per share	10.35
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.97	N/A	N/A	$6.60 per share	4.37
RYTM Rhythm Pharmaceuticals	$136.86M	42.04	N/A	N/A	$0.35 per share	258.40
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.37	N/A	N/A	N/A	-1,095.02%	-68.39%	-55.74%	8/11/2025 (Estimated)
DOVA Dova Pharmaceuticals	-$72.28M	-$2.60	N/A	N/A	N/A	-544.09%	-101.60%	-67.21%	N/A
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	115.34	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
ZIOP ZIOPHARM Oncology	-$79.98M	-$0.43	N/A	N/A	N/A	N/A	-92.84%	-72.46%	N/A

Latest ZIOP, APRE, DOVA, RYTM, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
DOVA Dova Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.90	5.90
DOVA Dova Pharmaceuticals	0.41	5.64	5.37
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
ZIOP ZIOPHARM Oncology	0.18	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
DOVA Dova Pharmaceuticals	33.03%
KNSA Kiniksa Pharmaceuticals International	53.95%
RYTM Rhythm Pharmaceuticals	N/A
ZIOP ZIOPHARM Oncology	51.03%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
DOVA Dova Pharmaceuticals	60.30%
KNSA Kiniksa Pharmaceuticals International	53.48%
RYTM Rhythm Pharmaceuticals	6.10%
ZIOP ZIOPHARM Oncology	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.53 million	4.78 million	No Data
DOVA Dova Pharmaceuticals	115	28.80 million	N/A	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
ZIOP ZIOPHARM Oncology	105	216.15 million	204.91 million	Optionable

ZIOP, APRE, DOVA, RYTM, and KNSA Headlines

Recent News About These Companies

TCRT stock touches 52-week low at $1.62 amid market challenges

January 30, 2025 | msn.com

Best Global Universities for Oncology

September 11, 2024 | usnews.com

FDA fast-tracks Merck's cancer blockbuster-in-waiting

July 28, 2024 | pharmaphorum.comP

BMS signs $475m cancer immunotherapy deal with Dragonfly

July 23, 2024 | pharmaphorum.comP

Childhood Cancers

February 17, 2024 | curetoday.comC

Alx Oncology Holdings (ALXO)

February 10, 2024 | investing.com

Pediatric Hematology-Oncology Fellowship

February 5, 2024 | bcm.eduB

Alaunos Therapeutics: Other Events, Financial Statements And Exhibits

January 31, 2024 | cbonds.comC

CG Oncology Inc

January 31, 2024 | reuters.com

Oncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients

December 21, 2023 | medscape.comM

Immuno-Oncology

December 19, 2023 | ajmc.comA

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?

December 18, 2023 | markets.businessinsider.com

Exploring Patient-Centered Handoffs in Surgical Oncology

December 10, 2023 | medscape.comM

Association of Community Cancer Centers

October 14, 2023 | ajmc.comA

Oncology News and Research

September 19, 2023 | news-medical.netN

WBSPH 2024 - Oncology

September 15, 2023 | newsweek.comN

Kris on Oncology

September 6, 2023 | medscape.comM

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

August 29, 2023 | thestreet.com

Oncology Cases & Quizzes

August 14, 2023 | medscape.comM

Ziopharm’s palifosfamide fails in first-line STS…

June 20, 2023 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIOP, APRE, DOVA, RYTM, and KNSA Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.68 +0.06 (+3.37%)

As of 10:50 AM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Dova Pharmaceuticals NASDAQ:DOVA

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.84 +0.75 (+2.65%)

As of 10:51 AM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Rhythm Pharmaceuticals NASDAQ:RYTM

$90.44 +1.08 (+1.21%)

As of 10:51 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time